ECHO — Acalabrutinib plus bendamustine-rituximab versus placebo plus bendamustine-rituximab in previously untreated mantle cell lymphoma (ECHO)

Phase 3 · Mantle Cell Lymphoma

Population

Previously untreated mantle cell lymphoma in patients not eligible for autologous stem cell transplant.

Primary Endpoint

Progression-free survival

Rationale

Second-generation BTK inhibitors transformed relapsed mantle cell lymphoma. ECHO tests whether adding acalabrutinib to first-line bendamustine-rituximab improves outcomes over chemoimmunotherapy alone.

What It Could Change

Could bring a second-generation BTK inhibitor into first-line chemoimmunotherapy for mantle cell lymphoma.